Theratechnologies Inc.

Equities

TH

CA88338H7040

Pharmaceuticals

Market Closed - Toronto S.E. 03:59:51 2024-03-28 pm EDT 5-day change 1st Jan Change
2.23 CAD +12.63% Intraday chart for Theratechnologies Inc. +31.18% +4.21%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Theratechnologies To Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology Platform MT
Theratechnologies Brief: To Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology Platform MT
Theratechnologies to Phase Down Preclinical Oncology Research Program MT
Theratechnologies to Wind Down Preclinical Research, Focus on Ovarian Cancer Study MT
Theratechnologies Inc. Appoints Jordan Zwick to Its Board of Directors and as Member of the Audit Committee CI
Theratechnologies Initiates Higher Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer MT
Theratechnologies Inc. Initiates Increased Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer CI
Theratechnologies Inc. Announces Board Changes CI
Theratechnologies Down 30% In US Premarket -- Receives Refusal To File Letter From FDA MT
Theratechnologies Shares Sink Premarket After FDA Refusal to File Letter DJ
Theratechnologies Brief: Down 21% In US Premarket As Says Received Refusal To File Letter For Trogarzo Intramuscular Method Of Administration SBLA From FDA MT
Theratechnologies Inc. Receives Refusal to File Letter for Trogarzo Intramuscular Method of Administration sBLA from FDA CI
Transcript : Theratechnologies Inc., Q4 2023 Earnings Call, Feb 21, 2024
Theratechnologies Reports Record Quarterly Revenue of US$23.5 Million, Q4 Net Loss of $0.08 Per Share MT
Theratechnologies Inc. Reports Earnings Results for the Full Year Ended November 30, 2023 CI
Theratechnologies Brief: Q4 Revenue US$23.452 Million; Guidance for 2024 set to $87-90 million in annual revenue and a positive Adjusted EBITDA in Range of $13-15 million for FY24 MT
Theratechnologies Inc. Provides Earnings Guidance for the Year 2024 CI
North American Morning Briefing : Stock Futures -2- DJ
Theratechnologies Announces Publication of Peer-Reviewed Article That Highlights TH1902 Mechanism of Action MT
Theratechnologies Brief: Announcing Publication in Frontiers in Immunology that "Deepens Understanding" of Sudocetaxel Zendusortide (TH1902) Molecular Mechanism of Action MT
Theratechnologies Inc. Announces Publication in Frontiers in Immunology That Deepens Understanding of Sudocetaxel Zendusortide Molecular Mechanism of Action CI
Theratechnologies Completes Enrollment of 6 Patients in Phase 1 Trial of Sudocetaxel Zendusortide In Advanced Ovarian Cancer MT
Theratechnologies Brief: Adds Sudy milestone further extends momentum for Co's lead PDC candidate and oncology clinical development program MT
Theratechnologies Brief: Says Completed Enrollment Of First Six Patients In Updated Phase 1 Clinical Trial Of Sudocetaxel Zendusortide In Advanced Ovarian Cancer MT
Theratechnologies Completes Enrollment of First Six Patients in Updated Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer CI
Chart Theratechnologies Inc.
More charts
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.23 CAD
Average target price
8 CAD
Spread / Average Target
+258.74%
Consensus
  1. Stock
  2. Equities
  3. Stock Theratechnologies Inc. - Toronto S.E.
  4. News Theratechnologies Inc.
  5. Theratechnologies : Earnings Flash (TH.TO) THERATECHNOLOGIES Reports Q2 Revenue US$17.787 Million, Up 4% Vs Year Earlier